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A link between smooth muscle cell death and
extracellular matrix degradation during vascular
atrophy
Richard D. Kenagy, PhD,a Seung-Kee Min, MD, PhD,b Eileen Mulvihill, PhD,a and
Alexander W. Clowes, MD,a Seattle, Wash; and Seoul, Korea
Objective: High blood flow induces neointimal atrophy in polytetrafluoroethylene (PTFE) aortoiliac grafts and a tight
external PTFE wrap of the iliac artery induces medial atrophy. In both nonhuman primate models, atrophy with loss of
smooth muscle cells and extracellular matrix (ECM) begins at<4 days. We hypothesized that matrix loss would be linked
to cell death, but the factors and mechanisms involved are not known. The purpose of this study was to determine
commonly regulated genes in these two models, which we hypothesized would be a small set of genes that might be key
regulators of vascular atrophy.
Methods:DNAmicroarray analysis (Sentrix Human Ref 8; Illumina, San Diego, Calif;23,000 genes) was performed on
arterial tissue from the wrap model (n 9) and graft neointima from the graft model (n 5) 1 day after wrapping or the
switch to high flow, respectively. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was also
performed. Expression of this vascular atrophy gene set was also studied after Fas ligand-induced cell death in cultured
smooth muscle cells and organ cultured arteries.
Results:Microarray analysis showed 15 genes were regulated in the same direction in both atrophy models: 9 upregulated
and 6 downregulated. Seven of nine upregulated genes were confirmed by qRT-PCR in both models. Upregulated genes
included the ECM-degrading enzymes ADAMTS4, tissue plasminogen activator (PLAT), and hyaluronidase 2; possible
growth regulatory factors, including chromosome 8 open reading frame 4 and leucine-rich repeat family containing 8; a
differentiation regulatory factor (musculoskeletal embryonic nuclear protein 1); a dead cell removal factor (ficolin 3); and
a prostaglandin transporter (solute carrier organic anion transporter family member 2A1). Five downregulated genes
were confirmed but only in one or the other model. Of the seven upregulated genes, ADAMTS4, PLAT, hyaluronidase 2,
solute carrier organic anion transporter family member 2A1, leucine-rich repeat family containing 8, and chromosome 8
open reading frame 4 were also upregulated in vitro in cultured smooth muscle cells or cultured iliac artery by treatment
with FasL, which causes cell death. However, blockade of caspase activity with Z-VAD inhibited FasL-mediated cell
death, but not gene induction.
Conclusion: Seven gene products were upregulated in two distinctly different in vivo nonhuman primate vascular atrophy
models. Induction of cell death by FasL in vitro induced six of these genes, including the ECM-degrading factors ADAMTS4,
hyaluronidase 2, and PLAT, suggesting a mechanism by which the program of tissue atrophy coordinately removes
extracellular matrix as cells die. These genes may be key regulators of vascular atrophy. (J Vasc Surg 2011;54:182-91.)
Clinical Relevance: This study identifies a small number of genes regulated in two distinct models of vascular atrophy in
nonhuman primates. Some are involved in degradation of extracellular matrix, cell death, or cell differentiation. The
function of others is less clear, but all may be fundamental regulators of vascular atrophy and may represent future
therapeutic targets. A pharmacologic therapy based on the induction of vascular atrophy of established intimal lesions in
restenotic stented vessels (arteries, vein grafts, and arteriovenous fistulas) would enable treatment of only those patients
that develop stenosis rather than all patients as required when prevention of neointimal hyperplasia is the strategy.
s
w
l
t
o
o
a
l
o
t
y
r
tFrom the Department of Surgery, University of Washington, Seattlea; and
the Department of Surgery, Seoul National University College of Medi-
cine, Seoul.b
Supported by National Institutes of Health HL30946 and RR00166.
Competition of interest: none.
Additional material for this article may be found online at www.jvascsurg.org.
Reprint requests: Alexander W. Clowes, MD, Department of Surgery,
University of Washington, PO Box 356410, 1959 NE Pacific St, Seattle,
WA 98195-6410 (e-mail: clowes@u.washington.edu).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00m
Copyright © 2011 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.12.070
182A novel approach for the treatment of restenotic
tented arteries, vein grafts, and arteriovenous fistulas
ould be to induce atrophy of the established intimal
esion. This would enable treatment of only affected pa-
ients rather than all patients as required when prevention
f neointimal hyperplasia is the strategy.1 Intimal atrophy
ccurs naturally at late times in stented arteries in rats, pigs,
nd in most humans,2-5 but little is known about its regu-
ation. Therefore, we have established two different models
f vascular atrophy in baboons. In the first model, neoin-
ima forms over 2 months in aortoiliac polytetrafluoroeth-
lene (PTFE) grafts and is then induced to regress in
esponse to a marked increase in blood flow after construc-
ion of a femoral arteriovenous fistula.6,7 In the second
odel, the media of a normal iliac artery regresses in
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Volume 54, Number 1 Kenagy et al 183response to a tight PTFE wrap.8 In both models, loss of
smooth muscle cells (SMCs) and matrix degradation are
apparent by 4 days,7,8 and SMC death documented by
terminal deoxynucleotide transferase-mediated deoxy uri-
dine triphosphate nick-end labeling (TUNEL) is observed
in the PTFE graft model by 1 day.9
We hypothesized that matrix loss would be linked to
cell death, but the factors and mechanisms involved are not
known. For example, we previously tested the hypothesis
that nitric oxide (NO) is required for graft neointimal
atrophy based on the observations that endothelial NO
synthase (NOS) is increased in the regressing graft endo-
thelium10 and that NO can inhibit SMC proliferation.11
However, we found that pharmacologic blockade of NOS
did not affect the neointima.7 To further test the hypothesis
that extracellular matrix (ECM) loss is linked to cell death,
we have determined gene expression after 1 day in both
baboon models of vascular atrophy to define a subset of
genes common to both models and have determined the
effect of FasL-induced cell death on induction of these
genes in vitro.
METHODS
Animal care and procedures in this study were con-
ducted at the University of Washington Regional Primate
Research Center in accordance with state and federal laws
and under protocols approved by the University of Wash-
ington Institutional Animal Care and Use Committee and
the Regional Primate Research Center. Animal care and
handling complied with the Guide for the Care and Use of
Laboratory Animals issued by the Institute of Laboratory
Animal Resources, Commission on Life Sciences, National
Research Council, Washington, DC, National Academies
Press, 1996 (http://stills.nap.edu/readingroom/books/
labrats/).
Baboon model with PTFE graft. Ten male baboons
received bilateral aortoiliac, 60-m internodal distance,
4-mm unreinforced PTFE (Gore-Tex, W.L. Gore and As-
sociates, Flagstaff, Ariz) bypass grafts, as described previ-
ously.7 Two months after the bypass surgery, a single distal
1-cm arteriovenous fistula was created distal to a patent
graft between the superficial femoral artery and the femoral
vein. Femoral artery flow was measured by duplex ultra-
sound imaging just before and 1 day after fistula formation.
Baboon model with PTFE wrap. The common iliac
arteries of 10 male baboons were tightly wrapped with a
piece of 60-m internodal distance, unreinforced PTFE
graft material by wrapping the collapsed artery and a
2.5-mm diameter rod together and removing the rod after
sewing the graft material closed.8 The contralateral artery
was dissected free from the surrounding tissue as a control.
RNA isolation and quantification. PTFE graft inti-
mal tissue or wrapped and unwrapped arteries were har-
vested 1 day after fistula surgery or wrapping, respectively,
and snap-frozen in RNAlater (Ambion, Carlsbad, Calif).
Total RNA was prepared from graft neointimas and iliac
arteries using the RNeasy fibrous tissue midi kit as de-
scribed by the manufacturer (Qiagen, Valencia, Calif).riefly, frozen tissue was pulverized under liquid nitrogen,
omogenized in extraction buffer, and treated with protei-
ase K. RNA from cultured cells was obtained using the
Neasy Mini Kit (Qiagen) with the syringe and needle
ethod of shearing. RNA preparations were treated with
Nase1 before purification on the kit columns. RNA qual-
ty was assessed using the RNA 6000 Nano assay on the
100 Bioanalyzer (Agilent, Palo Alto, Calif); A260/280
atios and yield were determined using the NanoDrop
D1000 spectrophotometer (Thermo Scientific, Waltham,
ass).
Microarray analysis. The Illumina Sentrix Human
ef-8 system (Illumina Inc, San Diego, Calif) was used
ccording to the manufacturer’s instructions. In brief, total
NAwas used for complementary DNA (cDNA) synthesis,
ollowed by amplification and labeling to create biotin-
RNA probes (Ambion MessageAmp kit; Ambion, Austin
ex). Hybridization, washing, blocking, development, and
canning were performed as directed by the manufacturer.
ummarized bead intensities for noncontrol probes were
uantile normalized. Several quality metrics were applied
nd indicated RNA degradation in two graft model samples
nd one sample of the wrap model. These three arrays plus
heir paired arrays were removed from the analysis. Statis-
ical significance of gene expression differences was com-
uted using Significance Analysis of Microarrays (SAM)
oftware (http://www-stat.stanford.edu/tibs/SAM/)12
ithout a threshold for fold-change.
Five collections of gene sets (GO Biological Process,
P; GO Molecular Function, MF; GO Cellular Compo-
ent, CC; and the C1 and C2 sets from Subramanian et
l13) were used for gene set analysis. Information about C1
nd C2 sets can be found at http://www.broad.mit.edu/
sea/msigdb/index.jsp. The software used has been de-
cribed.13,14 Analysis was restricted to gene sets with a
inimum of 10 and a maximum of 500 genes. If a partic-
lar gene set is enriched in the wrapped or high-flow group,
he online Results files of log2 expression contrasts (eg,
rapped to unwrapped) are presented online and have the
ord “positive” in the file name if a gene set is enriched in
he wrapped or high-flow group and “negative” in the file
ame if it is enriched in the unwrapped or normal-flow
roup.
Quantitative reverse-transcription polymerase chain
eaction. Quantitative reverse transcription polymerase
hain reaction (qRT-PCR) was performed using the
500 Fast real-time PCR system (Applied Biosystems,
oster City, Calif) according to the manufacturer’s in-
tructions using Taqman primers and probes purchased
rom Applied Biosystems and SensiMix master mix from
uantace Ltd (London, United Kingdom). Human probes
orGas6 and PLAT did not work in baboon tissues; therefore,
ew primers were chosen using Primer3 (http://frodo.wi.
it.edu/cgi-bin/primer3/primer3_www.cgi) and obtained
rom Integrated DNA Technologies (Coralville, Iowa):
Gas6 (human): 5=-CGGAATCTGGTCATCAAGGT-3=
and 5=-TCTTCTCCGTTCAGCCAGTT-3=;
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July 2011184 Kenagy et alPLAT (human): 5=-CCCAGATCGAGACTCAAAGC-3=
and 5=-TGGGGTTCTGTGCTGTGTAA-3=;
18S (mammalian): 5=-AAACGGCTACCACATCCAAG-3=
and 5=-CCTCCAATGGATCCTCGTTA-3=.
qRT-PCR for Gas6 and PLAT was performed using
SYBR Green SensiMix DNA kit (Quantace) according to
the manufacturer’s instruction. Melting curves and size of
product were tested to determine specificity. 18S was used
as an endogenous control.
In vitro studies. Baboon aortic SMCs were cultured
in Dulbecco’s modified Eagle medium (DMEM) with 10%
calf serum. SMCs were seeded at 20,000/cm2 in six-well
plates with 10% calf serum. The next day, the cell layer was
washed with phosphate-buffered saline, and medium was
changed to DMEM without serum plus recombinant hu-
man soluble Fas ligand (FasL)/FLAG fusion protein (50
ng/mL), anti-FLAG (2 g/mL; both from Axxora, San
Diego, Calif), and 1.5 g/mL cycloheximide. After 6 and
24 hours RNAwas extracted using RNeasy kits as described
Fig 1. Venn diagram of significantly regulated genes during flow-
mediated graft neointimal atrophy and wrap-mediated medial ar-
terial atrophy. Fifteen genes were increased or decreased in both
baboon models.
Table I. Genes regulated in both baboon models of vascu
Gene RefSeq No.
ADAMTS4 NM_005099 A disintegrin and
thrombospond
FCN3 NM_173452 Ficolin 3
MUSTN1 NM_205853 Musculoskeletal
protein 1 (Mu
HIST2H2AC NM_003517 Histone 2H2ac
PLAT NM_000931 Tissue plasminog
LRRC8 XM_026998 Leucine-rich repe
C8orf4 NM_020130 Thyroid cancer 1
SLCO2A1 NM_005630 Solute carrier org
family, membe
HYAL2 NM_003773 Hyaluronidase 2
FABP3 NM_004102 Fatty acid bindin
FMOD NM_002023 Fibromodulin
OGN NM_014057 Osteoglycin
MATN2 NM_030583 Matrilin 2
TNNC1 NM_003280 Troponin C type
GAS6 NM_000820 Growth arrest spValues are the fold of unwrapped or normal flow, respectively. Values in parenthebove. For experiments with Z-VAD, Z-VAD (50 mol;
D Biosciences, San Jose, Calif) was added (or equivalent
imethyl sulfoxide to controls and FasL treated cultures)
0 minutes before the addition of FasL, anti-FLAG, and
ycloheximide, as above. After 24 hours, medium was
emoved and spun at 1000g to remove floating cells for
ounting. Cell layers were harvested for RNA as above.
For organ culture experiments, baboon iliac arteries
ere obtained from the Washington National Primate Re-
earch Center tissue program. Periadventitial tissue was
emoved and the arteries were opened longitudinally. Ar-
erial tissue (1.5-cm length) was incubated in a 12-well
late containing 2 mL of 10 mmol HEPES/DMEM (pH
.4), with or without FasL/FLAG fusion protein (100
g/mL), anti-FLAG (2 g/mL), and 1.5 g/mL cyclo-
eximide. Arteries were snap-frozen 6 hours later and
tored at –80°C until extraction of RNA using fibrous
Neasy kits, as described above.
Statistical analysis. Values reported are the mean 
tandard error of the mean. Statistical differences (other
han microarray data) were tested using a one-tailed Wil-
oxon signed rank test.
ESULTS
PTFE grafts in three animals were occluded just before
he fistula formation, so the fistulas were made in seven
nimals. RNA from one wrapped artery and two graft
eointimas was degraded and was excluded from further
nalysis. Nine pairs of wrapped arteries and five pairs of graft
ntima were analyzed by microarray.
Genes regulated during vascular atrophy in vivo.
aired comparisons of gene expression by microarray were
ade between wrapped and unwrapped arteries and be-
ween high-flow and normal-flow PTFE graft intimas. In
he wrapped arteries, we found 404 upregulated genes and
07 downregulated genes among the 24,357 genes exam-
rophy
e Wrap Graft
lloproteinase with
otifs 4
2.94 (0) 1.58 (0)
2.00 (0) 2.26 (0)
yonic nuclear
1)
1.98 (0) 3.00 (0)
1.74 (0) 1.47 (0)
tivator 1.66 (0) 1.47 (8.15)
mily 8 containing 1.62 (0) 1.37 (8.15)
1.49 (0) 1.81 (0)
anion transporter
(PGT)
1.39 (0.17) 2.15 (0)
1.34 (0) 1.47 (8.22)
tein 3 0.74 (0.84) 0.64 (6.30)
0.77 (0.71) 0.60 (6.30)
0.77 (0.58) 0.57 (6.30)
0.77 (0.32) 0.70 (6.30)
0.56 (0) 0.73 (8.18)
protein 6 0.66 (0) 0.67 (6.30)lar at
Nam
meta
in m
embr
stang
en ac
at fa
anic
r 2A1
g pro
1
ecificses are Q values from significance analysis of microarrays (SAM) analysis.
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Volume 54, Number 1 Kenagy et al 185ined using an estimated false discovery rate of 1% (Sup-
plementary Table I, online only). In the graft neointimas,
we found 58 upregulated genes and 26 downregulated
genes (Supplementary Table II, online only). In this case,
we used a 10% false discovery rate for the analysis of the
graft intimas because of the small number of samples.
A comparison of the genes that were significantly
changed in the two models demonstrates the degree of
difference between these two models (Fig 1). However, we
did identify 15 genes regulated in the same direction in
both models (Table I). The correlation of expression be-
tween the two models for these 15 genes was significant
(Spearman r  0.76, P  .001).
To validate the microarray data, qRT-PCR of the 15
genes was performed. All but one of the nine genes up-
regulated in wrapped arteries was verified (Fig 2, A-I).
These included three genes involved in ECM regulation –
ADAMTS4, PLAT (tissue plasminogen activator), and
HYAL2 (hyaluronidase 2). The other five genes were
MUSTN1 (Mustang 1), FCN3 (ficolin 3), SLCO2A1 (sol-
ute carrier organic anion transporter 2A1, also called the
prostaglandin transporter or PGT), C8orf4 (thyroid cancer
1 or TC1), and LRRC8 (leucine rich repeat containing 8).
In the graft intimas PLAT, HYAL2, MUSTN1, FCN3,
SLCO2A1, and C8orf4 showed the same trend (P  .063;
only four paired samples were available for analysis), and
ADAMTS4 was previously verified at the protein and
mRNA levels.15 Among the six downregulated genes,
MATN2 (matrilin 2), TNNC1 (troponin C), and FABP3
(fatty acid binding protein 3) were verified in the wrap
model (Fig 2, J-O), whereas GAS6 and OGN (osteoglycin)
demonstrated a trend to be decreased in the graft (P 
.063).
Gene set analysis of atrophy in vivo. The results of
gene set analysis of themicroarray data were consistent with
the results from analysis of individual genes. A comparison
of the two atrophy models yielded a small number of gene
sets regulated in common. The two models shared only
four gene sets of the Biological Process collection. Three
were significantly higher (GO:0045892 negative regula-
tion of transcription, DNA-dependent; GO:0006974 re-
sponse to DNA damage stimulus; and GO:0042127 regu-
lation of cell proliferation; gene set lengths of 42, 23, and
40, respectively) and one was significantly lower (GO:
0050819 negative regulation of coagulation; gene set
length of 11) comparing wrapped with unwrapped and
high flow to normal flow (see Supplementary Figs I to IV,
online only).
Gene regulation during apoptosis of SMCs in vitro.
A small number of genes are regulated in the same manner
in the two models of vascular atrophy. Because cell death is
a significant aspect of both of these models, it is possible
that these genes are regulated as part of a cell death path-
way. To explore this possibility, we studied the effect of
FasL on gene expression; we have previously shown that
FasL at this dose kills 30% of baboon SMCs by 24
hours.15 Of the seven upregulated genes, tissue plasmino-
gen activator (PLAT), the prostaglandin transporter oSLCO2A1), C8orf4, and LRRC8 were increased by FasL
n vitro (Fig 3, A-H), but hyaluronidase 2 (HYAL2),
ustang 1 (MUSTN1), and ficolin 3 (FCN3) were not
hanged. We have previously reported that ADAMTS4
RNA is increased fivefold after FasL treatment.15 As a
ositive control we showed that monocyte chemoattractant
rotein (MCP)-1, which is induced by FasL,16 was also
ncreased by FasL (27 18-fold and 12 6-fold of control
t 6 and 24 hours, respectively; mean  SD of two experi-
ents).
The observation that only five of seven genes that were
pregulated in vivo were also upregulated in the cultured
MC death model raised the possibility that these differ-
nces may result from the lack of endothelial cells or the
ack of a physiologic ECM in the in vitro model of cell
eath. Therefore, we also studied the effect of a 6-hour
reatment with FasL on the expression of the upregulated
enes in cultured baboon arteries. In contrast with the
ultured SMCs, FasL induced hyaluronidase 2 in the artery
Fig 4, B). Tissue plasminogen activator (PLAT), the pros-
aglandin transporter (SLCO2A1),C8orf4, andADAMTS4
ere induced in the artery to a similar degree as observed in
MCs (Fig 4. A, D, E, andH). FCN 3 andMUSTN1 were
ot induced by FasL, and the modest stimulation of
RRC8 was not statistically significant.
To determine whether blocking apoptosis would
revent induction of the atrophy-related genes by FasL,
e used the pan-caspase inhibitor, Z-VAD. This series of
xperiments was performed with a different baboon
MC line than the one used for data presented in Fig 3.
asL induced the prostaglandin transporter (SLCO2A1),
8orf4, and ADAMTS4, but not PLAT and LRRC8.
his is not surprising given the variability of gene induc-
ion also observed in vivo (Fig 2). The addition of 50
mol Z-VAD completely blocked the production of
oating SMCs by FasL at 24 hours, but Z-VAD did not
nhibit FasL-mediated increases in ADAMTS4, C8orf4,
nd SLCO2A1 (Table II).
ISCUSSION
We have demonstrated that only a small number of
enes are upregulated in both nonhuman primate models
f vascular atrophy, namely medial atrophy in the tightly
rapped iliac artery and neointimal atrophy in a PTFE graft
ubjected to a switch from normal to high blood flow. The
omparison of two distinctly different models of atrophy,
ne caused by changes in shear stress and the other caused
y changes in wall stress, was purposely used to narrow the
esults obtained from microarray analysis. We chose the
-day time, at which time there is increased cell death and
ecreased cell proliferation in the PTFE graft model, but
efore large changes occur in the wall mass.9 Because there
s essentially no proliferation in the artery model, we ex-
ected that there might be changes in both models in genes
elated to cell death. Our results support the conclusion
hat these commonly regulated genes may play a funda-
ental role in vascular atrophy. In addition, the fact that six
f the seven atrophy-associated genes are also induced by
JOURNAL OF VASCULAR SURGERY
July 2011186 Kenagy et alFig 2. qRT-PCR of genes found by microarray analysis to be regulated in the PTFE wrap and PTFE graft models of
vascular atrophy. A, ADAMTS4 (see Kenagy et al15 for graft data), (B) Ficolin 3 (FCN3), (C)Mustang 1 (MUSTN1),
(D) Histone 2H2A (HIST2H2A), (E) tissue plasminogen activator (PLAT), (F) LRRC8, (G) C8orf4 or TC1, (H)
SCLO2A1 or the prostaglandin transporter, PGT, (I) hyaluronidase 2 (HYAL2), (J) troponin C (TNNC1), (K)
GAS6, (L) matrilin 2 (MATN2), (M) osteoglycin (OGN), (N) fatty acid binding protein 3 (FABP3), and (O)
fibromodulin (FMOD). Each point represents a triplicate determination of paired samples of RNA from an individual
animal’s iliac arteries or PTFE graft intimas. Values are expressed as the ratio of wrapped/unwrapped or high blood
flow/normal blood flow. The dotted line represents a ratio of 1, and the solid line shows the mean value. *P  .02;
#P  .063.
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Volume 54, Number 1 Kenagy et al 187the ligand for the death receptor Fas further suggests that
these genes are an important part of the vascular cell death
program. These ideas are supported by the observation that
ficolin 3 binds to and mediates the uptake of apoptotic cells
by macrophages.17 Although there are few macrophages in
the regressing tissue in the baboon atrophy models,7,8
SMCs also can phagocytose dead cells.18 Also, one-third of
the upregulated genes degrade components of the ECM,
loss of which is a major feature of vascular atrophy. For
example, the ECM constitutes 80% of neointimal vol-
ume,6,19 and loss of cross sectional area at 4 days in both
models occurs with no change in nuclear density, consistent
with a loss of ECM along with cells. Although there is a
preferential loss of versican in the PTFE graft ECM, com-
ponents of the ECM appear to be lost proportionately in
the wrapped arteries.8,20
Tissue plasminogen activator activates plasminogen to
Fig 3. The effect of FasL on expression of (A) tissue pl
(C) LRRC8, (D) prostaglandin transporter (SLCO2A1)
1 (MUSTN1) in cultured smooth muscle cells expressed
SEM of 3 experiments.plasmin, and plasmin degrades numerous ECM components tnd can also activate some matrix-degrading matrix metallo-
roteinase (MMP) family members.21,22 Hyaluronidase 2
egrades the promigratory and proproliferative ECM that
yaluronan forms with versican,23 and it also generates20-
Da fragments of hyaluronan that may induce MCP-1 and
ther inflammatory factors.24,25 ADAMTS4 can degrade a
umber of ECMproteins, including versican, aggrecan, bigly-
an, matrilins, and brevican.26-30
Cell death and ECM degradation. Our data add to
he literature linking cell death to enzymatic degradation of
CM. Several classes of proteases are increased in dying
ells31-34 and may be responsible for maintaining the cell-
CM balance by removing the ECM associated with dying
ells. They can also cause cell death via reduction ofmatrix/
ell attachment factors required for viability. For example,
eskinen et al35 reported that chymase causes SMC death
y degrading the integrin-binding matrix factor, fibronec-
ogen activator (PLAT), (B) hyaluronidase2 (HYAL2),
C8orf4 (TC-1), (F) ficolin 3 (FCN3), and (G)Mustang
of 6- or 24-hour control. *P .05 vs control; meanasmin
, (E)
as foldin. Of particular relevance to our study, plasmin generated
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cause SMCdeath.36 Because tissue plasminogen activator is
induced by FasL, it may be involved in a positive feedback
Fig 4. The effect of FasL on expression of (A) tissue pl
(C) LRRC8, (D) prostaglandin transporter (SLCO2A1)
(MUSTN1), (H)ADAMTS4 in arterial organ culture exp
 standard error of the mean of 3 to 4 experiments.
Table II. Effect of Z-VAD on FasL-induced gene
expression and number of floating smooth muscle cells
(SMC)
Gene FasL FasL  ZVAD
ADAMTS4 2.19  0.54 2.09  0.53
C8orf4 3.28  0.67 3.58  0.51
LRRC8 1.23  0.25 1.44  0.17
PLAT 0.66  0.14 0.73  0.15
SLCO2A1 2.50  0.46 4.52  1.02
Floating SMCs 12.0  4.3 0.2  0.1
Values are expressed as the fold of control (mean SEM of 3 experiments).loop to facilitate cell death. In addition, it is intriguing that rissue plasminogen activator inhibits the accumulation of
ntimal SMCs and causes positive arterial remodeling after
arotid artery injury.37
With regards to ADAMTS4, SMCdeath and ADAMTS4
re both increased in the PTFE graft neointima 1 day after the
witch to high blood flow,7,15 and dying intimal SMCs ex-
ress ADAMTS4.15 Furthermore, we have shown that AD-
MTS4 cleaves versican, a major constituent of graft neoin-
ima.15,26 The cleavage fragments of versican may be
mportant during neointimal atrophy.38 This has been shown
ecently for regression of cardiac outflow tract and interdigital
issue in the mouse.39,40 ADAMTS5, -9, and -20 coopera-
ively clip versican at the Glu-441-Ala-442 bond (the same
ond cleaved by ADAMTS426) and generate an N-terminal
ragment that increases apoptosis in interdigital web cells.
hreshold levels of the versican N-terminal fragment may be
ogen activator (PLAT), (B) hyaluronidase2 (HYAL2),
C8orf4 (TC-1), (F) ficolin 3 (FCN3), (G) Mustang 1
d as fold of control. *P .05 vs control; †P .06; meanasmin
, (E)
resseequired for tissue regression.
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genes. The function of the other upregulated gene prod-
ucts associated with atrophy is less clear. SLCO2A1 (PGT)
transports prostaglandins into cells where they can be de-
graded.41,42 Prostaglandins of the D, E, and F series are
transported at a high rate, thromboxane at an intermediate
rate, and prostacyclin analogs at a low rate.43,44 Because
SMCs have been reported to synthesize PGE2, PGI2, and
PGD2,
45-48 increased SLCO2A1 might be expected to
have the greatest impact on reducing local levels of PGE2
and PGD2, which use the receptors, EP1 through EP4 and
DP1 and DP2, respectively. Although prostaglandin recep-
tor expression has not been measured in these atrophy
models and these receptors can mediate opposite effects
(eg, PGE2 receptors EP1 and EP3 induce vasoconstriction,
whereas EP2 and EP4 induce vasodilatation
49), it is of
interest that EP4 appears to mediate intimal hyperplasia.
Activation of EP4 increases ductus intimal cushion forma-
tion,50 and PGE2 may also activate the thromboxane re-
ceptor,51,52 knockout of which leads to decreased neoin-
tima formation after arterial injury.53 These data suggest
the possibility that SLCO2A1-mediated loss of local PGE2
might remove a pro-proliferative signal. C8orf4, which is
overexpressed in thyroid and breast cancers,54,55 causes
anchorage-independent growth when overexpressed in im-
mortalized epithelial cells,56 to mediate interleukin-1–
induced proliferation of a dendritic-like cell line,57 and to
inhibit Chibby,58 a negative regulator of -catenin signal-
ing, which stimulates SMC proliferation and inhibits cell
death.59,60
Musculoskeletal embryonicnuclear protein1 (MUSTN1) is
required for differentiation of chondrocytes and myo-
blasts.61,62 Whether MUSTN1 affects SMC differentiation
is uncertain. Message levels of SMC differentiation genes
such as SM22 (TAGLN), smoothelin (SMTN), desmin
(DES), and calponin (CNN1) are decreased in the wrap
model, but not in the graft neointima. Other smooth
muscle differentiation genes, such as smooth muscle myo-
sin heavy chain, smooth muscle -actin (ACTA2), and
caldesmon, are not altered in either model (Supplementary
Tables I and II, online only). Finally, LRRC8, a putative
four-pass transmembrane protein with many leucine-rich
repeats in the extracellular domain, is required for B-cell
development.63 Thus, tissue plasminogen activator,
SLOC2A1, and MUSTN1 may provide antiproliferative and
prodifferentiation functions, and C8orf4 may be a counter-
regulatory factor to moderate cell death.
Potential role of FasL in vivo. How cell death and
gene expression are regulated during vascular atrophy is not
evident. Nevertheless, FasL/Fas interactions mediate SMC
apoptosis during spiral artery remodeling, after arterial
injury, and after increased shear stress in vitro.64-66 This
pathway may be operative in the baboon models, because
shear stress may be increased in the tightly wrapped artery
as well as in the PTFE graft. Further, FasL induces six of the
seven atrophy-associated upregulated genes in cultured
SMCs and arteries (Figs 3 and 4). The observation that
activation of Fas in apoptosis-resistant cells increases aMP2 and MMP9 in a caspase-independent manner67
lso links Fas activation to the baboon atrophy models,
ecause baboon SMCs are apoptosis resistant (ie, cyclohex-
mide is required with FasL for killing), and we have previ-
usly reported that levels of MMP2 and MMP9 are in-
reased after 7 days of high blood flow in the PTFE graft
odel.68
The in vitro data indicate that FasL-mediated atrophy
ene induction is independent of caspase-induced cell
eath (Table II), suggesting the possibility that a signaling
ascade observed in glioblastoma cells that consists of an src
inase, PI3K, and PKB may be involved.67 FasL also in-
uces MCP-1 in SMCs in vitro (our results and Schaub et
l16), and increased blood flow increases MCP-1 in the
TFE graft model after 4 days (online Table 8C in Hsieh et
l9), but not after 1 day (Supplementary Tables I and II,
nline only). In addition, induction of MCP-1 is partially
ediated by IL-1 (Schaub et al16), which also induces
DAMTS4 and hyaluronidase 2.69,70 These data suggest
hat a Fas/IL-1 pathway may be operative in vivo during
trophy and account for the upregulation of some of the
trophy-associated genes.
Vascular cells expressing atrophy-associated genes.
lthough the cells expressing atrophy-associated genes in
ivo have not been determined, we have demonstrated
hat cultured SMCs regulate the expression of tissue
lasminogen activator, LRRC8, SLCO2A1, C8orf4, and
DAMTS4. However, endothelial cells also express tissue
lasminogen activator, SLCO2A1, ADAMTS4, hyaluron-
dase, and ficolin 3.71,72 The endothelium is clearly the cell
xposed to the greatest shear stress, and many genes have
een reported to be regulated by shear stress, including
issue plasminogen activator. Our observation that hyal-
ronidase 2 was not increased in cultured SMCs, but was
ncreased in the cultured artery, is consistent with endothe-
ial cell expression of this gene.
ONCLUSIONS
Seven genes are upregulated in two distinctly different
odels of nonhuman primate vascular atrophy. Most of
hese genes are also upregulated during induction of cell
eath in vitro, including the ECM-degrading factors tissue
lasminogen activator, ADAMTS4, and hyaluronidase-2.
urther studies are required to determine the specific roles
f these and the other atrophy-associated gene products
nd their suitability as therapeutic targets to induce vascular
trophy in established restenotic disease.
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nd tissue processing.
11
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
JOURNAL OF VASCULAR SURGERY
July 2011190 Kenagy et alAUTHOR CONTRIBUTIONS
Conception and design: RK, AC
Analysis and interpretation: RK, SM, AC
Data collection: RK, SM, EM
Writing the article: RK
Critical revision of the article: RK, SM, EM, AC
Final approval of the article: RK, SM, EM, AC
Statistical analysis: RK
Obtained funding: RK, AC
Overall responsibility: AC
RK and SM contributed equally to this work.
REFERENCES
1. Min SK, Kenagy RD, Clowes AW. Induction of vascular atrophy as a
novel approach to treating restenosis. A review. J Vasc Surg 2008;47:
662-70.
2. Finn AV, Gold HK, Tang A, Weber DK, Wight TN, Clermont A, et al.
A novel rat model of carotid artery stenting for the understanding of
restenosis in metabolic diseases. J Vasc Res 2002;39:414-25.
3. Kim WH, Hong MK, Virmani R, Kornowski R, Jones R, Leon MB.
Histopathologic analysis of in-stent neointimal regression in a porcine
coronary model. Coron Artery Dis 2000;11:273-7.
4. Kuroda N, Kobayashi Y, Nameki M, Kuriyama N, Kinoshita T, Okuno
T, et al. Intimal hyperplasia regression from 6 to 12 months after
stenting. Am J Cardiol 2002;89:869-72.
5. Asakura M, Ueda Y, Nanto S, Hirayama A, Adachi T, Kitakaze M, et al.
Remodeling of in-stent neointima, which became thinner and transpar-
ent over 3 years 	 Serial angiographic and angioscopic follow-up.
Circulation 1998;97:2003-6.
6. Mattsson EJ, Kohler TR, Vergel SM, Clowes AW. Increased blood flow
induces regression of intimal hyperplasia. Arterioscler ThrombVasc Biol
1997;17:2245-9.
7. Berceli SA, Davies MG, Kenagy RD, Clowes AW. Flow-induced neo-
intimal regression in baboon polytetrafluoroethylene grafts is associated
with decreased cell proliferation and increased apoptosis. J Vasc Surg
2002;36:1248-55.
8. Min SK, Kenagy RD, Jeanette JP, Clowes AW. Effects of external
wrapping and increased blood flow on atrophy of the baboon iliac
artery. J Vasc Surg 2008;47:1039-47.
9. Hsieh PCH, Kenagy RD, Mulvihill ER, Jeanette JP, Wang X, Chang
CMC, et al. Bonemorphogenetic protein 4: Potential regulator of shear
stress-induced graft neointimal atrophy. J Vasc Surg 2006;43:150-8.
10. Mattsson EJR, Kohler TR, Vergel SM, Clowes AW. Increased blood
flow induces regression of intimal hyperplasia. Arterioscler Thromb
Vascul Biol 1997;17:2245-9.
11. Chen L, Daum G, Forough R, Clowes M, Walter U, Clowes AW.
Overexpression of human endothelial nitric oxide synthase in rat vascu-
lar smooth muscle cells and in balloon-injured carotid artery. Circ Res
1998;82:862-70.
12. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci U S A
2001;98:5116-21.
13. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,
Gillette MA, et al. Gene set enrichment analysis: A knowledge-based
approach for interpreting genome-wide expression profiles. Proc Natl
Ac Sc U S A 2005;102:15545-50.
14. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann
Appl Stat 2007;1:107-29.
15. Kenagy RD, Min S-K, Clowes AW, Sandy JD. Cell death-associated
ADAMTS4 and versican degradation in vascular tissue. J Histochem
Cytochem 2009;57:889-97.
16. Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, Ramachandran
RK, et al. Fas/FADD-mediated activation of a specific program of
inflammatory gene expression in vascular smooth muscle cells. NatMed
2000;6:790-6.17. Honore C, Hummelshoj T, Hansen BE, Madsen HO, Eggleton P,
Garred P. The innate immune component ficolin 3 (Hakata antigen)mediates the clearance of late apoptotic cells. Arthritis Rheum
2007;56:1598-607.
8. Fries DM, Lightfoot R, Koval M, Ischiropoulos H. Autologous apo-
ptotic cell engulfment stimulates chemokine secretion by vascular
smooth muscle cells. Am J Pathol 2005;167:345-53.
9. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after
arterial injury. Lab Invest 1983;49:208-15.
0. Kenagy RD, Fischer JW, Lara S, Sandy JD, Clowes AW, Wight TN.
Accumulation and loss of extracellular matrix during shear stress-mediated
intimal growth and regression in baboon vascular grafts. J Histochem
Cytochem 2005;53:131-40.
1. Hu JH, Du L, Chu T, Otsuka G, Dronadula N, Jaffe M, et al.
Overexpression of urokinase by plaque macrophages causes histological
features of plaque rupture and increases vascular matrix metalloprotei-
nase activity in aged apolipoprotein E-null mice. Circulation 2010;121:
1637-44.
2. Plow EF, Hoover-Plow J. The functions of plasminogen in cardiovas-
cular disease. Trends Cardiovas Med 2004;14(5):180-6.
3. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan- and
versican-rich pericellular matrix is required for proliferation and migra-
tion of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol
1999;19:1004-13.
4. de la Motte C, Nigro J, Vasanji A, Rho H, Kessler S, Bandyopadhyay S,
et al. Platelet-derived hyaluronidase 2 Cleaves hyaluronan into Frag-
ments that Trigger monocyte-mediated production of proinflammatory
cytokines. Am J Pathol 2009;174:2254-64.
5. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair.
Annu Revs Cell Dev Biol 2007;23:435-61.
6. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C,
Rodriguez-Mazaneque JC, et al. Versican V1 proteolysis in human
aorta in vivo occurs at the Glu 441 -Ala 442 bond, a site that is cleaved
by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 2001;276:
13372-8.
7. Frank JE, Thompson VP, Brown MP, Sandy JD. Removal of O-linked
and N-linked oligosaccharides is required for optimum detection of
NITEGE neoepitope on ADAMTS4-digested fetal aggrecans: implica-
tions for specific N-linked glycan-dependent aggrecanolysis at Glu373–
Ala374. Osteoarthritis Cartilage 2009;17:777-81.
8. Nakamura H, Fujii Y, Inoki I, Sugimoto K, Tanzawa K, Matsuki H, et
al. Brevican is degraded bymatrix metalloproteinases and aggrecanase-1
(ADAMTS4) at different sites. J Biol Chim 2000;275:38885-90.
9. Klatt AR, Klinger G, Paul-Klausch B, Kuhn G, Renno JH, Wagener R,
et al. Matrilin-3 activates the expression of osteoarthritis-associated
genes in primary human chondrocytes. FEBS Lett 2009;583:3611-7.
0. Melching LI, Fisher WD, Lee ER, Mort JS, Roughley PJ. The cleavage
of biglycan by aggrecanases. Osteoarthritis Cartilage 2006;14:1147-54.
1. Piva TJ, Davern CM, Francis KG, Chojnowski GM, Hall PM, Ellem
KA. Increased ecto-metallopeptidase activity in cells undergoing ap-
optosis. J Cell Biochem 2000;76:625-38.
2. Cowan KN, Leung WCY, Mar C, Bhattacharjee R, Zhu YH, Rabino-
vitch M. Caspases from apoptotic myocytes degrade extracellular ma-
trix: a novel remodeling paradigm. FASEB J 2005:19:1848-50.
3. O’MullaneMJ, Baker MS. Loss of cell viability dramatically elevates cell
surface plasminogen binding and activation. Exp Cell Res 1998;242:
153-64.
4. Levkau B, Kenagy RD, Karsan A, Weitkamp B, Clowes AW, Ross R, et
al. Activation of metalloproteinases and their association with integrins:
an auxiliary apoptotic pathway in human endothelial cells. Cell Death
Differ 2002;9:1360-7.
5. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase
induces smooth muscle cell apoptosis by a mechanism involving fi-
bronectin degradation and disruption of focal adhesions. Arterioscler
Thromb Vasc Biol 2003;23:238-43.
6. Meilhac O, Ho-Tin-Noe B, Houard X, Philippe M, Michel JB, Angles-
Cano E. Pericellular plasmin induces smooth muscle cell anoikis.
FASEB J 2003;17:1301-3.
7. Parfyonova Y, Plekhanova O, SolomatinaM, Naumov V, Bobik A, Berk
B, et al. Contrasting effects of urokinase and tissue-type plasminogen
activators on neointima formation and vessel remodelling after arterial
injury. J Vasc Res 2004;41:268-76.
55
5
6
6
6
6
6
6
6
6
6
6
7
7
7
S
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 19138. Kenagy RD, Plaas AH, Wight TN. Versican degradation and vascular
disease. Trends Cardiovasc Med 2006;16:209-15.
39. Kern CB, Norris RA, Thompson RP, Argraves WS, Fairey SE, Reyes L,
et al. Versican proteolysis mediates myocardial regression during out-
flow tract development. Dev Dynam 2007;236:671-83.
40. McCulloch DR, Nelson CM, Dixon LJ, Silver DL, Wylie JD, Lindner
V, et al. ADAMTS metalloproteases generate active versican fragments
that regulate interdigital web regression. Dev Cell 2009;17:687-98.
41. Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of
prostaglandin signal termination: in vitro reconstitution with the pros-
taglandin transporter and prostaglandin 15 dehydrogenase. Mol Phar-
macol 2004;65:973-8.
42. Chang H-Y, Locker J, Lu R, Schuster VL. Failure of postnatal ductus
arteriosus closure in prostaglandin transporter-deficient mice. Circula-
tion 2010;121:529-36.
43. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL. Identi-
fication and characterization of a prostaglandin transporter. Science
1995;268:866-9.
44. Lu R, Kanai N, Bao Y, Schuster VL. Cloning, in vitro expression, and
tissue distribution of a human prostaglandin transporter cDNA(hPGT).
J Clin Invest 1996;98:1142-9.
45. Okahara K, Sun B, Kambayashi J. Upregulation of prostacyclin
synthesis–related gene expression by shear stress in vascular endothelial
Cells. Arterioscler Thromb Vasc Biol 1998;18:1922-6.
46. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential
induction of cyclooxygenase-2 in human arterial and venous smooth
muscle--role of endogenous prostanoids. Arterioscler Thromb Vasc
Biol 1998;18:1655-61.
47. Bishop-Bailey D,Warner TD. PPARgamma; ligands induce prostaglan-
din production in vascular smooth muscle cells: indomethacin acts as a
peroxisome proliferator-activated receptor-
 antagonist. FASEB J.
2003;17:1925-7.
48. Bayston T, Ramessur S, Reise J, Jones KG, Powell JT. Prostaglandin E2
receptors in abdominal aortic aneurysm and human aortic smooth
muscle cells. J Vasc Surg 2003;38:354-9.
49. Norel X. Prostanoid receptors in the human vascular wall. Scientific-
WorldJournal 2007;7:1359-74.
50. Yokoyama U, Minamisawa S, Quan H, Akaike T, Jin M, Otsu K, et al.
Epac1 is upregulated during neointima formation and promotes vascu-
lar smooth muscle cell migration. Am J Physiol Heart Circ Physiol
2008;295:H1547-55.
51. Boersma JI, Janzen KM, Oliveira L, CrankshawDJ. Characterization of
excitatory prostanoid receptors in the human umbilical artery in vitro.
Br J Pharmacol 1999;128:1505-12.
52. Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS, et al.
EP4 prostanoid receptor-mediated vasodilatation of human middle
cerebral arteries. Br J Pharmacol 2004;141:580-5.
53. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et
al. Role of prostacyclin in the cardiovascular response to thromboxane
A2. Science 2002;296:539-41.
54. Chua EL, Young L, Wu WM, Turtle JR, Dong Q. Cloning of TC-1
(C8orf4), a novel gene found to be overexpressed in thyroid cancer.
Genomic 2000;69:342-7.
55. SundeM,McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP,
et al. TC-1 is a novel tumorigenic and natively disordered protein
associated with thyroid cancer. Cancer Res 2004;64:2766-73.
56. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple
interacting oncogenes on the 8p11-p12 amplicon in human breast
cancer. Cancer Res 2006;66:11632-43. a7. Kim Y, Kim J, Park J, Bang S, Jung Y, Choe J, et al. TC1(C8orf4) is
upregulated by IL-1beta/TNF-alpha and enhances proliferation of
human follicular dendritic cells. FEBS Lett 2006;580:3519-24.
8. Jung Y, Bang S, Choi K, Kim E, Kim Y, Kim J, et al. TC1 (C8orf4)
enhances the Wnt/beta-catenin pathway by relieving antagonistic ac-
tivity of Chibby. Cancer Res 2006;66:723-8.
9. Ezan J, Leroux L, Barandon L, Dufourcq P, Jaspard B, Moreau C, et al.
FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway,
controls vascular cell proliferation in vitro and in vivo. Cardiovasc Res
2004;63:731-8.
0. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A role for
the beta-catenin/T-cell factor signaling cascade in vascular remodeling.
Circ Res 2002;90:340-7.
1. Gersch RP, Hadjiargyrou M. Mustn1 is expressed during chondrogen-
esis and is necessary for chondrocyte proliferation and differentiation in
vitro. Bone 2009;45:330-8.
2. Liu C, Gersch RP, Hawke TJ, Hadjiargyrou M. Silencing of Mustn1
inhibits myogenic fusion and differentiation. Am J Physiol Cell Physiol
2010;298:C1100-8.
3. Sawada A, Takihara Y, Kim JY, Matsuda-Hashii Y, Tokimasa S, Fujisaki
H, et al. A congenital mutation of the novel gene LRRC8 causes
agammaglobulinemia in humans. J Clin Invest 2003;112:1707-13.
4. Matter CM, Chadjichristos CE,Meier P, von Lukowicz T, LohmannC,
Schuler PK, et al. Role of endogenous Fas (CD95/Apo-1) ligand in
balloon-induced apoptosis, inflammation, and neointima formation.
Circulation 2006;113:1879-87.
5. Harris LK. Review: trophoblast-vascular cell interactions in early preg-
nancy: how to remodel a vessel. Placenta 2010;31(suppl 1):S93-S8.
6. Apenberg S, Freyberg MA, Friedl P. Shear stress induces apoptosis in
vascular smooth muscle cells via an autocrine Fas/FasL pathway.
Biochim Biophys Res Commun 2003;310:355-9.
7. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et
al. Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma.
Cancer Cell 2008;13:235-48.
8. Kenagy RD, Fischer JW, Davies MG, Berceli SA, Hawkins SM, Wight
TN, et al. Increased plasmin and serine proteinase activity during
flow-induced intimal atrophy in baboon PTFE grafts. Arterioscler
Thromb Vasc Biol 2002;22:400-4.
9. Patwari P, Gao G, Lee JH, Grodzinsky AJ, Sandy JD. Analysis of
ADAMTS4 and MT4-MMP indicates that both are involved in aggre-
canolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Carti-
lage 2005;13:269-77.
0. Tanimoto K, Yanagida T, Tanne Y, Kamiya T, Huang Y, Mitsuyoshi T,
et al. Modulation of hyaluronan fragmentation by interleukin-1beta in
synovial membrane cells. Ann Biomed Eng 2010;38:1618-25.
1. Ni C-W, Qiu H, Rezvan A, Kwon K, Nam D, Son DJ, et al. Discovery
of novel mechanosensitive genes in vivo using mouse carotid artery
endothelium exposed to disturbed flow. Blood 2010;116:e66-e73.
2. Bhasin M, Yuan L, Keskin D, Otu H, Libermann T, Oettgen P.
Bioinformatic identification and characterization of human endothelial
cell-restricted genes. BMC Genomics 2010;11:342.
ubmitted Jul 14, 2010; accepted Dec 11, 2010.
Additional material for this article may be found online
t www.jvascsurg.org.
JOURNAL OF VASCULAR SURGERY
July 2011191.e1 Kenagy et alSupplementary Table I. Genes significantly changed by a
Analysis of Microarrays (SAM) software with a false discovetight PTFE wrap. Data were analyzed by Significance
ry rate of 1.0%.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e2Supplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
July 2011191.e3 Kenagy et alSupplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e4Supplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
July 2011191.e5 Kenagy et alSupplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e6Supplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
July 2011191.e7 Kenagy et alSupplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e8Supplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
July 2011191.e9 Kenagy et alSupplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e10Supplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
July 2011191.e11 Kenagy et alSupplementary Table I. Continued
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e12Supplementary Table II. Genes significantly changed by
Analysis of Microarrays (SAM) software with a false discovehigh flow in a PTFE graft. Data were analyzed by Significance
ry rate of 10%.
JOURNAL OF VASCULAR SURGERY
July 2011191.e13 Kenagy et alSupplementary Table II. Continued
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e14Supplementary Table II. Continued
JOURNAL OF VASCULAR SURGERY
July 2011191.e15 Kenagy et alSupplementary Fig I (online only). Gene set GO:0045892
“negative regulation of transcription, DNA-dependent” was sig-
nificantly enriched in (A) high-flow graft neointimas and (B)
wrapped arteries compared with unwrapped arteries and normal
flow grafts, respectively.Supplementary Fig I, A (online only). Continued.
Supplementary Fig I, B (online only). Continued.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e16Supplementary Fig I, A (online only). Continued.
JOURNAL OF VASCULAR SURGERY
July 2011191.e17 Kenagy et alSupplementary Fig I, B (online only). Continued.Supplementary Fig I, B (online only). Continued.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e18Supplementary Fig II (online only). Gene set GO:0006974
“response to DNA damage stimulus” was significantly enriched in
(A) high-flow graft neointimas and (B)wrapped arteries compared
with unwrapped arteries and normal flow grafts, respectively.Supplementary Fig II, A (online only). Continued. Supplementary Fig II, A (online only). Continued.
JOURNAL OF VASCULAR SURGERY
July 2011191.e19 Kenagy et alSupplementary Fig II, B (online only). Continued.Supplementary Fig II, B (online only). Continued.Supplementary Fig II, B (online only). Continued.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e20Supplementary Fig III (online only). Gene set GO:0042127
“regulation of cell proliferation” was significantly enriched in (A)
high-flow graft neointimas and (B) wrapped arteries compared
with unwrapped arteries and normal flow grafts, respectively.Supplementary Fig III, A (online only). Continued.
Supplementary Fig III, B (online only). Continued.
JOURNAL OF VASCULAR SURGERY
July 2011191.e21 Kenagy et alSupplementary Fig III, A (online only). Continued.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e22Supplementary Fig III, B (online only). Continued.Supplementary Fig III, B (online only). Continued.
JOURNAL OF VASCULAR SURGERY
July 2011191.e23 Kenagy et alSupplementary Fig IV (online only). Gene set GO:0050819
“negative regulation of coagulation” was significantly enriched in
(A) normal flow graft neointimas and (B) unwrapped arteries
compared with high-flow grafts and wrapped arteries, respectively.Supplementary Fig IV, A (online only). Continued.Supplementary Fig IV, A (online only). Continued.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Kenagy et al 191.e24Supplementary Fig IV, B (online only). Continued.Supplementary Fig IV, B (online only). Continued.Supplementary Fig IV, B (online only). Continued.
